Methods and devices for using isoperillyl alcohol

Abstract

The present invention provides for a method of treating a disease such as cancer, comprising the step of administering to a patient a therapeutically effective amount of an isomer or analog of monoterpene or sesquiterpene (or its derivative), such as an isoperillyl alcohol. The present invention also provides for a method of treating a disease comprising the step of administering to a patient a therapeutically effective amount of a derivative of an isomer or analog of monoterpene or sesquiterpene, such as an isoperillyl alcohol carbamate. The derivative may be an isoperillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The route of administration may vary, including inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

1 - 23 . (canceled) 
     
     
         24 . A pharmaceutical composition comprising an isoperillyl alcohol carbamate, wherein the isoperillyl alcohol carbamate is an isoperrilyl alcohol covalently bound via a carbamate linking group to rolipram. 
     
     
         25 - 28 . (canceled) 
     
     
         29 . The pharmaceutical composition of  claim 24 , wherein the pharmaceutical composition is administered by inhalation, intranasally, orally, intravenously, subcutaneously or intramuscularly. 
     
     
         30 . The pharmaceutical composition of  claim 24 , wherein the pharmaceutical composition is admixed or coformulated with a therapeutic agent. 
     
     
         31 . (canceled) 
     
     
         32 . A process for making an isoperillyl alcohol carbamate, comprising the step of reacting a first reactant of isoperillyl chloroformate with a second reactant, wherein the second reactant is rolipram. 
     
     
         33 . (canceled) 
     
     
         34 . The process of  claim 32 , wherein the reaction is carried out in the presence of acetone and a catalyst of potassium carbonate. 
     
     
         35 . (canceled) 
     
     
         36 . The process of  claim 32 , wherein the reaction is carried out in the presence of tetrahydrofuran and a catalyst of n-butyl lithium. 
     
     
         37 . The process of  claim 32 , wherein isoperillyl chloroformate is prepared by reacting isoperillyl alcohol with phosgene. 
     
     
         38 . The pharmaceutical composition of  claim 24 , wherein the isoperillyl alcohol is selected from the group consisting of (4-isopropylidene cyclohex-1-enyl)methanol, (4-isopropyl cyclohexa-1,3-dienyl)methanol, (4-isopropyl cyclohexa-1,4-dienyl)methanol, (4-isopropylphenyl)methanol and (4-isopropenylphenyl)methanol. 
     
     
         39 . The pharmaceutical composition of claim  1 , wherein the isoperillyl alcohol is 4-isopropylidene cyclohex-1-enyl)methanol. 
     
     
         40 . A method for treating a disease in a mammal, comprising the step of administering to the mammal the pharmaceutical composition of claim  1 . 
     
     
         41 . The method of claim  1 , wherein the disease is cancer. 
     
     
         42 . The method of claim  3 , wherein the cancer is a tumor of the nervous system. 
     
     
         43 . The method of claim  4 , wherein the tumor is a glioblastoma. 
     
     
         44 . The method of claim  6 , further comprising the step of treating the mammal with radiation. 
     
     
         45 . The method of claim  6 , further comprising the step of administering to the mammal a chemotherapeutic agent. 
     
     
         46 . The method of claim  6 , wherein the pharmaceutical composition is administered by inhalation, intranasally, orally, intravenously, subcutaneously or intramuscularly. 
     
     
         47 . A method for treating a disease in a mammal, comprising the step of administering to the mammal a therapeutically effective amount of an isoperillyl alcohol or an isoperillyl alcohol carbamate using a nasal delivery device. 
     
     
         48 . The method of claim  22 , wherein the nasal delivery device is selected from the group consisting of an intranasal inhaler, an intranasal spray device, an atomizer, a nebulizer, a metered dose inhaler (MDI), a pressurized dose inhaler, an insufflator, a unit dose container, a pump, a dropper, a squeeze bottle and a bi-directional device.